<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cco" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cco</book-part-id>
      <title-group>
        <title>Central Core Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Malicdan</surname>
            <given-names>May Christine V</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Undiagnosed Diseases Program, Office of the Director<break/>NIH Common Fund<break/>National Institutes of Health<break/>Bethesda, Maryland</aff>
          <email>malicdanm@mail.nih.gov</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nishino</surname>
            <given-names>Ichizo</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>National Center of Neurology and Psychiatry <break/>National Institute of Neuroscience<break/>Tokyo, Japan</aff>
          <email>nishino@ncnp.go.jp</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>16</day>
          <month>5</month>
          <year>2007</year>
        </date>
        <date date-type="updated">
          <day>4</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="celiac" document-type="chapter">Celiac Disease</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ccm" document-type="chapter">Cerebral Cavernous Malformation, Familial</related-object>
      <abstract id="cco.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Central core disease (CCD) is characterized by muscle weakness ranging from mild to severe. Most affected individuals have mild disease with symmetric proximal muscle weakness and variable involvement of facial and neck muscles. The extraocular muscles are often spared. Motor development is usually delayed, but in general, most affected individuals acquire independent ambulation. Life span is usually normal. Severe disease is early in onset with profound hypotonia often accompanied by poor fetal movement, spinal deformities, hip dislocation, joint contractures, poor suck, and respiratory insufficiency requiring assisted ventilation. The outcome ranges from death in infancy to survival beyond age five years. The weakness in CCD is not typically progressive.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of CCD is based on clinical findings of muscle weakness, the histopathologic findings of characteristic cores on muscle biopsy, and molecular genetic testing. Most CCD is associated with pathogenic variants in <italic toggle="yes">RYR1</italic>, the gene encoding the ryanodine receptor 1.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Physical therapy for hypotonia and weakness that may include stretching and mild to moderate low-impact exercise; assistive devices as needed for ambulation; orthopedic surgery as needed for scoliosis, congenital hip dislocation, foot deformities; respiratory support, breathing exercises, chest physiotherapy as needed; dietary supplementation and nasogastric or gastrostomy feeding as needed.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Intervention as needed to prevent respiratory compromise from scoliosis; immunization against influenza; prompt treatment of respiratory infection; mobility and physical therapy to prevent joint contractures.</p>
          <p><italic toggle="yes">Surveillance:</italic> Routine assessment of spine for scoliosis, joints for contractures, respiratory parameters (e.g., respiratory rate, peak expiratory flow rate [PEFR], forced vital capacity [FVC], and forced expiratory volume in one second [FEV1]), motor abilities to determine need for physical therapy, occupational therapy, assistive devices; sleep studies when signs of nocturnal hypoxia are present.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Although the actual risk for malignant hyperthermia susceptibility is unknown, it is prudent for individuals with CCD to avoid inhalational anesthetics and succinylcholine.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the <italic toggle="yes">RYR1</italic> pathogenic variant is known, it is appropriate to offer at-risk relatives molecular genetic testing to identify those with possible increased malignant hyperthermia susceptibility.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Central core disease (CCD) is usually inherited in an autosomal dominant (AD) manner but can be inherited in an autosomal recessive (AR) manner. Most individuals diagnosed with AD central core disease have an affected parent or an asymptomatic parent who has a pathogenic variant. The proportion of AD CCD caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown. Each child of an individual with AD CCD has a 50% chance of inheriting the pathogenic variant. The parents of a child with AR CCD are obligate heterozygotes and therefore carry one mutated allele. Heterozygotes (carriers) are often asymptomatic. At conception, each sib of an individual with AR CCD has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Prenatal diagnosis for pregnancies at increased risk for AD or AR CCD is possible once the pathogenic variant(s) have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cco.Diagnosis">
        <title>Diagnosis</title>
        <sec id="cco.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Diagnosis of central core disease <bold>should be suspected</bold> in individuals with the following features &#x02013; keeping in mind that this disorder has a wide spectrum of symptoms and presentations, from the absence of symptoms to severe features necessitating the use of ventilatory support:</p>
          <list list-type="bullet">
            <list-item>
              <p>In early-onset disease:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Hypotonia and generalized weakness, often accompanied by perinatal complications including poor fetal movement, respiratory insufficiency, and poor suck</p>
                </list-item>
                <list-item>
                  <p>Delayed motor milestones (Independent ambulation is commonly achieved between ages three and four years, but varies depending on the severity of the disease.)</p>
                </list-item>
                <list-item>
                  <p>Spinal deformities, congenital hip dislocation, high-arched palate, foot deformities, and joint contractures. Rarely, patients may show severe skeletal malformations such as those seen in <related-object link-type="booklink" source-id="gene" document-id="spondylocostal-d" document-type="chapter">spondylocostal dysostosis</related-object>.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In later-onset disease (rare):</p>
              <list list-type="bullet">
                <list-item>
                  <p>Mild symmetric myopathy, predominantly involving the proximal muscles</p>
                </list-item>
                <list-item>
                  <p>Mildly affected facial muscles</p>
                </list-item>
                <list-item>
                  <p>Occasional involvement of the extraocular muscles (Ophthalmoplegia is relatively common in the autosomal recessive forms.)</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="cco.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of central core disease <bold>is established</bold> in a proband with (1) a muscle biopsy demonstrating <bold>characteristic</bold> cores in a significant number of fibers on muscle biopsy, even in individuals who are seemingly asymptomatic and/or (2) molecular genetic testing that detects pathogenic variant(s) in <italic toggle="yes">RYR1</italic> (see <xref ref-type="table" rid="cco.T.summary_of_molecular_genetic_testi">Table 1</xref>).</p>
          <p>In the event that molecular testing is done first:</p>
          <list list-type="bullet">
            <list-item>
              <p>In a patient with classic clinical presentation of CCD, if the identified <italic toggle="yes">RYR1</italic> variant is known to be pathogenic, the necessity of muscle biopsy becomes less important and will only be used for classification.</p>
            </list-item>
            <list-item>
              <p>In a patient without visible clinical involvement, muscle biopsy will be of importance if there is a need to interpret <italic toggle="yes">RYR1</italic> variations of uncertain significance, in the absence of functional studies.</p>
            </list-item>
          </list>
          <p>
            <bold>Muscle biopsy</bold>
          </p>
          <p><bold>Histologic examination</bold> of muscle is essential to the diagnosis of central core disease. Diagnostic findings are the presence of a significant number of cores in type 1 fibers with the following characteristics (<xref ref-type="fig" rid="cco.F1">Figure 1B</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p>Often well demarcated</p>
            </list-item>
            <list-item>
              <p>May be centrally or peripherally located in the fibers</p>
            </list-item>
            <list-item>
              <p>Run down an appreciable length of the fiber on longitudinal sections</p>
            </list-item>
            <list-item>
              <p>Devoid of mitochondria</p>
            </list-item>
            <list-item>
              <p>Do not stain with oxidative enzyme stains (e.g., NADH-tetrazolium reductase, succinate dehydrogenase, cytochrome <italic toggle="yes">c</italic> oxidase)</p>
            </list-item>
            <list-item>
              <p>Deficient in phosphorylase activity and glycogen</p>
            </list-item>
            <list-item>
              <p>Sometimes surrounded by a thin rim of high oxidative enzyme activity, giving the appearance of "rimmed cores"</p>
            </list-item>
            <list-item>
              <p>On immunohistochemistry studies, distinct staining patterns that are restricted to the cores: RyR1 protein was focally depleted within the cores, while other proteins including DHPR[alpha]<sub>1</sub>s, triadin, SERCA1/2, and calsequestrin accumulated within or around the cores [<xref ref-type="bibr" rid="cco.REF.herasse.2007.57">Herasse et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>Less common but nonetheless important pathologic findings in the spectrum of cores include the following [<xref ref-type="bibr" rid="cco.REF.ferreiro.2002b.739">Ferreiro et al 2002b</xref>, <xref ref-type="bibr" rid="cco.REF.jungbluth.2002.284">Jungbluth et al 2002</xref>, <xref ref-type="bibr" rid="cco.REF.sewry.2002.930">Sewry et al 2002</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>More than one core can be observed within a single muscle fiber.</p>
            </list-item>
            <list-item>
              <p>The number of type 1 fibers with cores varies.</p>
            </list-item>
            <list-item>
              <p>The diameter of cores can vary.</p>
            </list-item>
            <list-item>
              <p>Foci of multiple minicores in focal areas can occur.</p>
            </list-item>
          </list>
          <p>Other pathologic characteristics of muscle:</p>
          <list list-type="bullet">
            <list-item>
              <p>Type 1 fiber predominance or uniformity</p>
            </list-item>
            <list-item>
              <p>Mild to moderate fiber size variation</p>
            </list-item>
            <list-item>
              <p>Minimal to moderate endomysial fibrosis. Marked fibrosis and increase in adipose tissue have been noted in several cases.</p>
            </list-item>
            <list-item>
              <p>Occasional increase in internal and central nuclei</p>
            </list-item>
          </list>
          <p>Note: (1) Nemaline bodies occurring together with cores have been seen in genetically confirmed cases of CCD. When rods are numerous this has sometimes been referred to as core-rod disease. In a large French pedigree demonstrating autosomal dominant inheritance, the association of this disease with <italic toggle="yes">RYR1</italic> pathogenic variants was confirmed [<xref ref-type="bibr" rid="cco.REF.monnier.2000.2599">Monnier et al 2000</xref>]. Interestingly, some cases of <related-object link-type="booklink" source-id="gene" document-id="nem" document-type="chapter">nemaline myopathy</related-object> may also show cores [<xref ref-type="bibr" rid="cco.REF.jungbluth.2002.284">Jungbluth et al 2002</xref>], blurring the pathologic distinction between the two disorders. (2) Facial muscle involvement and high-arched palate are almost always observed in infantile or childhood nemaline myopathy, but are rarely seen in CCD.</p>
          <p><bold>Ultrastructural studies</bold> show the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Virtual absence of mitochondria and sarcoplasmic reticulum (SR) in the core region. SR accumulation within the cores has been described on EM.</p>
            </list-item>
            <list-item>
              <p>Irregular zigzag pattern or complete disruption of the Z-lines but often preservation of the striation pattern</p>
            </list-item>
            <list-item>
              <p>Reduction in the intermyofibrillar space</p>
            </list-item>
          </list>
          <sec id="cco.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p>One genetic testing strategy is molecular genetic testing of <italic toggle="yes">RYR1.</italic> Sequence analysis is performed first followed by deletion/duplication analysis if no pathogenic variant is found (see <xref ref-type="table" rid="cco.T.summary_of_molecular_genetic_testi">Table 1</xref>).</p>
            <p>An alternative genetic testing strategy is use of a multi-gene panel that includes <italic toggle="yes">RYR1</italic> and other genes of interest (see <xref ref-type="sec" rid="cco.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
            <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            <p>Note: Although in the majority of patients CCD results from a single pathogenic variant in <italic toggle="yes">RYR1</italic>, individuals with biallelic pathogenic variants (autosomal recessive inheritance) have been reported; thus, the following considerations are important.</p>
            <p>If only one pathogenic variant is identified in a simplex case (i.e., a single occurrence in a family), it is difficult to distinguish between the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>A <italic toggle="yes">de novo</italic> dominant pathogenic variant</p>
              </list-item>
              <list-item>
                <p>Autosomal recessive inheritance with a known <italic toggle="yes">RYR1</italic> pathogenic variant on one allele and a second as-yet unidentified pathogenic variant on the second allele</p>
              </list-item>
            </list>
            <p>To resolve this issue, the following can be considered:</p>
            <list list-type="bullet">
              <list-item>
                <p>Testing both parents for the pathogenic variant (when possible) to confirm or exclude a <italic toggle="yes">de novo</italic> pathogenic variant</p>
              </list-item>
              <list-item>
                <p>If autosomal recessive inheritance is suspected, deletion/duplication analysis or next generation sequencing to identify the pathogenic variant on the second allele</p>
              </list-item>
            </list>
            <p><bold>More comprehensive genomic testing.</bold> If serial single-gene testing (and/or use of a multi-gene panel) has not confirmed a diagnosis in an individual with features of CCD, genomic testing may be considered. Such testing may include exome sequencing, genome sequencing, and mitochondrial sequencing. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            <table-wrap id="cco.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Central Core Disease</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">RYR1</italic>
                    </td>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis of select exons&#x000a0;<sup>2,&#x000a0;3</sup></td>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">47%-80%&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of entire <italic toggle="yes">RYR1</italic>&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_cco.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="cco.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="cco" object-id="cco.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="cco.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="cco.TF.1.2">
                  <label>2. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="cco.TF.1.3">
                  <label>3. </label>
                  <p>Exons sequenced vary by laboratory.</p>
                </fn>
                <fn id="cco.TF.1.4">
                  <label>4. </label>
                  <p>In autosomal dominant CCD [<xref ref-type="bibr" rid="cco.REF.monnier.2001.2581">Monnier et al 2001</xref>, <xref ref-type="bibr" rid="cco.REF.davis.2003.151">Davis et al 2003</xref>, <xref ref-type="bibr" rid="cco.REF.shepherd.2004.e33">Shepherd et al 2004</xref>]</p>
                </fn>
                <fn id="cco.TF.1.5">
                  <label>5. </label>
                  <p>Results from <xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al [2006]</xref>. Among 27 individuals diagnosed with CCD on muscle biopsy, sequence analysis of the entire coding region documented <italic toggle="yes">RYR1</italic> pathogenic variants in 93% [<xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al 2006</xref>], suggesting that CCD may not be a genetically heterogeneous disease, as previously thought.</p>
                </fn>
                <fn id="cco.TF.1.6">
                  <label>6. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="cco.TF.1.7">
                  <label>7. </label>
                  <p>No other locus heterogeneity has been identified. It is possible that other disorders with EC uncoupling could be within the spectrum of CCD, but more studies are warranted. Other candidate genes to be considered include those that code for proteins involved or associated with the triadin, which is the anatomic site of EC uncoupling, and include triadin, junctin, histidine-rich calcium-binding protein, calsequestrin, JP-45, and mitsugamin-29 [<xref ref-type="bibr" rid="cco.REF.treves.2005.577">Treves et al 2005</xref>] and dihydropyridine receptor, calmodulin, and inositol phospate 3 receptor. To date, no pathogenic variant in the genes encoding these proteins has been associated with CCD.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v20/n2/full/ejhg2011179a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="cco.REF.lillis.2012">Lillis et al 2012</xref>] for information on test characteristics including sensitivity and specificity.</p>
          </sec>
        </sec>
      </sec>
      <sec id="cco.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="cco.Clinical_Description">
          <title>Clinical Description</title>
          <p>The expressivity of central core disease (CCD) is variable even among family members, ranging clinically from mild (i.e., almost asymptomatic) to severe (i.e., ventilator-dependent) and histologically varying in the extent and localization of cores in the muscle fibers.</p>
          <p><bold>Mild disease</bold>. Most individuals have mild disease characterized by mild, symmetric weakness that preferentially affects the proximal muscles. The facial and neck muscles may be mildly involved in some cases. The extraocular muscles are often spared in the classic, autosomal dominant form, but are typically involved in the autosomal recessive form. Motor development is usually delayed, but in general, most affected individuals acquire independent ambulation. Hypotonia in infancy and respiratory insufficiency can also occur in those with mild disease. Life span is usually normal.</p>
          <p><bold>Muscle cramps</bold> have been documented in some individuals with CCD, and this may be associated with MH susceptibility.</p>
          <p><bold>Severe disease</bold> is characterized by infantile onset associated with profound hypotonia and respiratory dysfunction requiring continuous assisted ventilation. In severely affected individuals, death may result from respiratory infection or respiratory insufficiency.</p>
          <p><bold>Fetal akinesia</bold> has been associated with both autosomal dominant and autosomal recessive forms of <italic toggle="yes">RYR1</italic>-related CCD [<xref ref-type="bibr" rid="cco.REF.romero.2003.2341">Romero et al 2003</xref>]. The clinical phenotype consisted of severe hypotonia, arthrogryposis multiplex congenita, amyotrophy, and respiratory failure, requiring mechanical ventilation. The outcome, however, was variable (ranging from early death to survival beyond age five years).</p>
          <p><bold>Progression.</bold> CCD is not typically progressive, although slow progression has been reported. Scoliosis can be progressive, resulting in respiratory insufficiency.</p>
          <p><bold>Cognition</bold>. Intellectual ability is intact.</p>
          <p>
            <bold>Laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Serum creatine kinase concentration may be normal or mildly elevated.</p>
            </list-item>
            <list-item>
              <p>Electromyography may confirm the presence of myopathy and reveal brief, short action potentials and early recruitment.</p>
            </list-item>
          </list>
          <p><bold>Muscle magnetic resonance imaging.</bold> Muscle imaging has demonstrated that certain muscles are selectively and consistently involved in autosomal dominant <italic toggle="yes">RYR1</italic>-related myopathies, including quadriceps, sartorius, adductor magnus, soleus, gastrocnemius, and peroneal group; certain muscles are relatively spared, including rectus femoris, gracilis, adductor longus, and tibialis anterior [<xref ref-type="bibr" rid="cco.REF.jungbluth.2004.785">Jungbluth et al 2004</xref>]. These findings were supported by <xref ref-type="bibr" rid="cco.REF.fischer.2006.2217">Fischer et al [2006]</xref> who described distinct MRI findings in persons with CCD who have an <italic toggle="yes">RYR1</italic> pathogenic variant, including predominant involvement of the gluteus maximus, adductor magnus, sartorius, vastus intermediolateralis, soleus, and lateral gastrocnemius muscles, as compared to those who do not have an <italic toggle="yes">RYR1</italic> pathogenic variant. The rectus femoris, adductor longus, and gracilis are hypertrophied in some patients. MRI findings in autosomal recessive <italic toggle="yes">RYR1</italic>-related CCD are not as consistent.</p>
        </sec>
        <sec id="cco.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Although most <italic toggle="yes">RYR1</italic> pathogenic variants that result in CCD are inherited in an autosomal dominant manner, reports of autosomal recessive inheritance are increasing. It is not possible to predict the mode of inheritance based on the pathogenic variant alone.</p>
          <p>Some studies have shown that autosomal recessive CCD, often associated with <italic toggle="yes">RYR1</italic> pathogenic variants outside the C-terminal region, can be severe [<xref ref-type="bibr" rid="cco.REF.romero.2003.2341">Romero et al 2003</xref>, <xref ref-type="bibr" rid="cco.REF.zhou.2006b.2791">Zhou et al 2006b</xref>]. Thus, it may be possible to consider most autosomal dominant forms of CCD as milder in phenotype than autosomal recessive forms of CCD.</p>
          <p>In a study of 25 individuals with genetically confirmed CCD, <xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al [2006]</xref> determined that:</p>
          <list list-type="bullet">
            <list-item>
              <p>The 16 individuals with C-terminal <italic toggle="yes">RYR1</italic> pathogenic variants had certain clinical features including hypotonia during infancy, delayed motor development, and limb muscle weakness and certain pathologic findings on muscle biopsy that delineate C terminal pathogenic variants from other groups including (1) type 2 fiber deficiency and interstitial fibrosis, (2) characteristic cores with clearly demarcated borders that are observed in almost all type 1 muscle fibers, (3) higher than average frequency of "rimming" on the borders of these cores;</p>
            </list-item>
            <list-item>
              <p>Most individuals with CCD with at least one <italic toggle="yes">RYR1</italic> pathogenic variant outside the C-terminal region had only mild musculoskeletal abnormalities such as joint contractures and scoliosis. Inheritance was autosomal dominant, consistent with previous reports of mild CCD phenotype.</p>
            </list-item>
          </list>
          <p><related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter"><bold>Malignant hyperthermia susceptibility</bold></related-object>
<bold>(MHS)</bold>-related <italic toggle="yes">RYR1</italic> pathogenic variants are predominantly located in the hydrophilic N-terminal and central portions of the ryanodine receptor 1 (RyR1) protein, whereas CCD-related <italic toggle="yes">RYR1</italic> substitutions mainly occur in the hydrophobic pore-forming region of the channel [<xref ref-type="bibr" rid="cco.REF.monnier.2000.2599">Monnier et al 2000</xref>, <xref ref-type="bibr" rid="cco.REF.monnier.2001.2581">Monnier et al 2001</xref>, <xref ref-type="bibr" rid="cco.REF.davis.2003.151">Davis et al 2003</xref>, <xref ref-type="bibr" rid="cco.REF.zorzato.2003.379">Zorzato et al 2003</xref>]. Previous reports have asserted that persons without muscle disease who are susceptible to malignant hyperthermia (MH) have pathogenic variants in the C-terminal region of ryanodine receptor 1; however, limited histopathologic evaluation of these individuals has revealed the presence of cores that are not characteristic of the cores of CCD [<xref ref-type="bibr" rid="cco.REF.ibarra.2006.1146">Ibarra et al 2006</xref>]; thus, they are most appropriately labeled as having &#x0201c;MH with cores.&#x0201d;</p>
          <p>Individuals with CCD who have pathogenic variants in the N-terminal domain may have a higher probability of malignant hyperthermia susceptibility than those with pathogenic variants in the C-terminal domain [<xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al 2006</xref>].</p>
        </sec>
        <sec id="cco.Penetrance">
          <title>Penetrance</title>
          <p>In general, the penetrance of CCD-associated <italic toggle="yes">RYR1</italic> pathogenic variants is almost 100%. Clinical variability exists to some extent among affected members of the family</p>
        </sec>
        <sec id="cco.Nomenclature">
          <title>Nomenclature</title>
          <p>CCD has also been referred to as Shy-Magee syndrome, after the individuals who initially reported it.</p>
          <p>Some cases called core-rod disease are not associated with a <italic toggle="yes">RYR1</italic> pathogenic variant; thus, "core-rod disease" is not a true synonym for CCD.</p>
        </sec>
        <sec id="cco.Prevalence">
          <title>Prevalence</title>
          <p>An accurate incidence and prevalence of CCD, considered to be the most frequently occurring congenital myopathy, are unknown. By definition CCD is considered a rare disease by the Office of Rare Disease, implying that it affects fewer than 200,000 in the US population. A recent estimate of 1:100,000 was calculated among patients with genetic muscle disease in Northern England [<xref ref-type="bibr" rid="cco.REF.norwood.2009.3175">Norwood et al 2009</xref>]. In Japan, the carrier frequency for heterozygous <italic toggle="yes">RYR1</italic> pathogenic variants is reported to be as high as 1:2000 [<xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="cco.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter"><bold>Malignant hyperthermia susceptibility</bold></related-object>
<bold>(MHS)</bold> is a pharmacogenetic disorder of skeletal muscle calcium regulation resulting in uncontrolled skeletal muscle hypermetabolism. Manifestations of malignant hyperthermia (MH) are triggered by certain volatile anesthetics (i.e., halothane, isoflurane, sevoflurane, desflurane, enflurane) either alone or in conjunction with depolarizing muscle relaxants (succinylcholine). The triggering substances release calcium stores from the sarcoplasmic reticulum, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate. Affected individuals experience acidosis, hypercapnia, tachycardia, hypoxemia, rhabdomyolysis with subsequent increase in serum creatine kinase (CK), hyperkalemia with a risk of cardiac arrhythmia or even arrest, and myoglobinuria with a risk of renal failure. In nearly all cases, the first manifestations of MH, tachycardia, and tachypnea occur in the operating room, but MH may also occur in the early postoperative period. Death results unless the individual is promptly treated.</p>
        <p>A clinical grading scale helps determine if a malignant hyperthermia (MH) episode has occurred. Contracture testing, the standard diagnostic test for MH since the mid-1970s, relies on the in vitro measurement of contracture response of biopsied muscle to graded concentrations of caffeine and the anesthetic halothane. Alternatively, calcium-induced calcium release (CICR) test can be performed, but has only been done in Japan. (For further information see <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object>.)</p>
        <p><italic toggle="yes">RYR1</italic> is one of three known MHS-related genes. Domains 1 and 2 of <italic toggle="yes">RYR1</italic> are located in the soluble cytoplasmic regions of the protein and are hot spots for MH; however, pathogenic variants in these two domains have also been associated with CCD (see <xref ref-type="sec" rid="cco.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
        <p>The precise association of MHS and <italic toggle="yes">RYR1</italic> pathogenic variants is not clear and thus all individuals with a <italic toggle="yes">RYR1</italic> pathogenic variant are considered at risk for malignant hyperthermia and advised of appropriate precautions.</p>
        <p>In several reports cores have been present in muscle biopsy of persons proven to have MH, thus raising controversy as to whether these individuals have CCD with MHS or MHS with cores. For example, <xref ref-type="bibr" rid="cco.REF.ibarra.2006.1146">Ibarra et al [2006]</xref> reported that 50% of persons with MHS with <italic toggle="yes">RYR1</italic> pathogenic variants had cores on muscle pathology, although most cores appear not to be as well-demarcated as those found in CCD. It has been proposed that <italic toggle="yes">RYR1</italic> pathogenic variants can enhance sarcoplasmic reticulum calcium leak, which in turn increases reactive oxygen species production, subsequently leading to mitochondrial swelling and early structural changes in the muscle [<xref ref-type="bibr" rid="cco.REF.boncompagni.2009.21996">Boncompagni et al 2009</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter"><bold>Multiminicore disease</bold></related-object>
<bold>(MmD).</bold> The diagnosis of MmD is based on the presence of multiple "minicores" visible on muscle biopsy oxidative stains. Minicores are small zones of sarcomeric disorganization and/or diminished oxidative activity typically extending only a few sarcomeres in the fiber longitudinal axis that correlate with lack of mitochondria in muscle fibers. Because minicores are not specific to MmD, the diagnosis of MmD is based on the presence of minicores in a large proportion of muscle fibers associated with static or slowly progressive weakness and absence of findings diagnostic of other disorders.</p>
        <p>Four clinical categories of MmD have been identified: classic form (75% of individuals), moderate form with hand involvement (&#x0003c;10%), antenatal form with arthrogryposis multiplex congenita (&#x0003c;10%), and ophthalmoplegic form (&#x0003c;10%). Onset of the classic form is usually congenital or occurs in early childhood with neonatal hypotonia, delayed motor development, axial muscle weakness, scoliosis, and significant respiratory involvement (often with secondary cardiac impairment). Spinal rigidity of varying severity is present.</p>
        <p>Pathogenic variants in two genes account for about half the cases of MmD. Although further genetic heterogeneity is suggested, no other candidate region or gene has been identified .</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">SELENON</italic> (<italic toggle="yes">SEPN1</italic>) pathogenic variants inherited in an autosomal recessive manner account for about 30% of all cases of MmD and about 40% of cases of classic MmD.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">RYR1</italic> pathogenic variants inherited in an autosomal recessive manner account for some forms of MmD, and in particular, those with ophthalmoplegia. Ophthalmoplegia is an exclusion criterion for <italic toggle="yes">SELENON</italic> pathogenic variants.</p>
          </list-item>
        </list>
        <p><bold>Congenital neuromuscular disorder with uniform fiber type 1 (CNMDU1).</bold> CNMDU1 is pathologically defined by the almost exclusive presence of type 1 fibers in muscle sections (i.e., type 1 fibers comprise more than 99% of the fibers) and the absence of specific structural abnormalities such as cores and nemaline bodies.</p>
        <p>CNMDU1 histologic findings are thought to be an earlier manifestation of CCD, as an individual with pathologically confirmed CCD had a muscle biopsy consistent with CNMDU1 earlier in childhood [<xref ref-type="bibr" rid="cco.REF.sewry.2002.930">Sewry et al 2002</xref>]. Furthermore, <xref ref-type="bibr" rid="cco.REF.quinlivan.2003.1051">Quinlivan et al [2003]</xref> reported <italic toggle="yes">RYR1</italic> pathogenic variants in a family with CCD in which the youngest member showed uniform fiber typing, suggesting that adults have CCD while children had CNMDU1. These data imply that CNMDU1 is an earlier manifestation of the CCD spectrum; however, this may not be the case. Pathogenic variants in the C-terminal region of <italic toggle="yes">RYR1</italic> were identified in 40% of individuals with CNMDU1 [<xref ref-type="bibr" rid="cco.REF.sato.2008.114">Sato et al 2008</xref>]. In this report, electron microscopic analysis of a muscle biopsy from a person with CNMDU1 showed virtually normal histology, devoid of signs of early core formation, also suggesting that CNMDU1 may be a distinct entity and more possibly allelic to CCD. Moreover, there has been no report of overlap between the two disorders with respect to histologic findings (i.e., uniform type 1 fiber with cores in only a few fibers), casting doubt on the hypothesis that these two diseases belong to a single spectrum.</p>
        <p><bold>Centronuclear myopathy</bold> is a genetically heterogeneous disorder characterized clinically as congenital myopathy and the presence of centrally placed nuclei in a significant proportion of myofibers. So far, pathogenic variants have been identified in myotubularin (<italic toggle="yes">MTM1</italic>), dynamin 2 (<italic toggle="yes">DNM2</italic>), amphiphysin 2 (<italic toggle="yes">BIN1</italic>), and myotubularin-related protein 14 (<italic toggle="yes">MTMR14</italic>). <xref ref-type="bibr" rid="cco.REF.jungbluth.2007.338">Jungbluth et al [2007]</xref> reported an individual age 16 years who was diagnosed at age one year with centronuclear myopathy with multiple central nuclei in up to 50% of fibers and central accumulation of oxidative enzyme stains. However, muscle biopsy eight years later revealed some core-like areas, raising the suspicion of CCD. Molecular genetic testing revealed a <italic toggle="yes">de novo</italic> pathogenic missense variant in exon 90 of <italic toggle="yes">RYR1</italic>. These findings suggest that the presence of an increased number of fibers with centrally placed nuclei may be a part of the CCD spectrum.</p>
      </sec>
      <sec id="cco.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>The clinical findings of central core disease</bold> (CCD) are variable and not disease specific; they can be seen in other congenital myopathies. Thus, from a clinical standpoint CCD cannot be readily distinguished from other congenital myopathies, such as <related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter">multiminicore disease</related-object>, CNMDU1 (see <xref ref-type="sec" rid="cco.Genetically_Related_Allelic_Disorder">Allelic Disorders</xref>), the intermediate form of <related-object link-type="booklink" source-id="gene" document-id="nem" document-type="chapter">nemaline myopathy</related-object>, fingerprint body myopathy (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/305550">305550</ext-link>), <related-object link-type="booklink" source-id="gene" document-id="cftd" document-type="chapter">congenital fiber-type disproportion</related-object>, hyaline body myopathy (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/255160">255160</ext-link>), reducing body myopathy (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300717">300717</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300718">300718</ext-link>), and cylindrical spirals myopathy (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/160990">160990</ext-link>).</p>
        <p><bold>The 'central core' histologic changes</bold> are nonspecific and may occur in other myopathies. Cores that have been noted in CCD have also been reported with pathogenic variants in the following genes:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">SELENON</italic> (<italic toggle="yes">SEPN1</italic>). Pathogenic variants in this gene are also associated with <related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter">minicores</related-object> [<xref ref-type="bibr" rid="cco.REF.ferreiro.2002b.739">Ferreiro et al 2002b</xref>], but no individual with a <italic toggle="yes">SELENON</italic> pathogenic variant and the typical long, well-delimited central cores characteristic of CCD has been reported.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">MYH7</italic>, in hypertrophic cardiomyopathy</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">ACTA1</italic> and <italic toggle="yes">TNNT1</italic> in <related-object link-type="booklink" source-id="gene" document-id="nem" document-type="chapter">nemaline myopathy</related-object> [<xref ref-type="bibr" rid="cco.REF.ilkovski.2001.1333">Ilkovski et al 2001</xref>]. <italic toggle="yes">ACTA1</italic> pathogenic variants were found in a congenital myopathy with few cores on muscle biopsy [<xref ref-type="bibr" rid="cco.REF.kaindl.2004.842">Kaindl et al 2004</xref>]; like other disorders with cores, however, these disorders are better considered as myopathies with cores, not CCD.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">CFL2</italic>, encoding cofilin-2, has been associated with <related-object link-type="booklink" source-id="gene" document-id="nem" document-type="chapter">nemaline myopathy</related-object> with minicores [<xref ref-type="bibr" rid="cco.REF.agrawal.2007.162">Agrawal et al 2007</xref>].</p>
          </list-item>
          <list-item>
            <p>Structures similar to cores have been observed in the myofibers of individuals with neurogenic atrophy but are more appropriately called "target fibers" in this setting because of the darker bandaround the pale central area, giving it a target-like appearance. In addition, core-like lesions devoid of this band can also be seen conditions with neurogenic atrophy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="cco.Management">
        <title>Management</title>
        <sec id="cco.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with central core disease (CCD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic examination with attention to features of congenital myopathy (hypotonia, failure to thrive, joint contractures, scoliosis), weakness of the limbs, and muscle cramps</p>
            </list-item>
            <list-item>
              <p>Physical and occupational therapy assessments</p>
            </list-item>
            <list-item>
              <p>Evaluation for feeding difficulties, including assessment for sucking and ability to swallow</p>
            </list-item>
            <list-item>
              <p>Pulmonary function testing in most patients, especially those with scoliosis, hypotonia, signs of respiratory distress, and/or history of recurrent chest infections. History should be taken for symptoms of nocturnal hypoxia including early morning headaches, daytime drowsiness, loss of appetite, and deteriorating school performance.</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="cco.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Since prognosis is mainly influenced by respiratory status and scoliosis, treatment geared towards these manifestations is essential.</p>
          <p>Treatment depends on the severity of symptoms, but mainly consists of supportive measures and rehabilitation that address the following problems:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hypotonia and weakness. Patients may benefit from physical therapy. Interventions may include stretching programs and mild to moderate low-impact exercise; activities should be balanced in such a way that exhaustion is avoided.</p>
            </list-item>
            <list-item>
              <p>Scoliosis and joint contractures. Some patients may only require physical therapy, while others may need orthopedic surgery (e.g., scoliosis surgery, corrective surgery for congenital hip dislocation and foot deformities).</p>
            </list-item>
            <list-item>
              <p>Respiratory. Patients with more severe symptoms may require respiratory support. Breathing exercises and chest physiotherapy for handling secretions may also be beneficial.</p>
            </list-item>
            <list-item>
              <p>Feeding difficulties. Individuals may require diet supplementation and feeding by means of nasogastric/orogastric routes or gastrostomy.</p>
            </list-item>
          </list>
        </sec>
        <sec id="cco.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Secondary complications can include respiratory compromise from scoliosis; hence, orthopedic intervention may reduce the risk of this problem.</p>
          <p>Immunization against influenza is encouraged.</p>
          <p>Prompt treatment of respiratory infection is important.</p>
          <p>Joint contractures may be prevented by encouraging mobility and by active participation in physical therapy.</p>
        </sec>
        <sec id="cco.Surveillance">
          <title>Surveillance</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Routine assessment of the spine for scoliosis and joints for contractures</p>
            </list-item>
            <list-item>
              <p>Routine assessment of respiratory parameters such as respiratory rate, peak expiratory flow rate (PEFR), forced vital capacity (FVC), and forced expiratory volume in one second (FEV1)</p>
            </list-item>
            <list-item>
              <p>Sleep studies especially when patients show signs of nocturnal hypoxia</p>
            </list-item>
            <list-item>
              <p>Regular assessment of motor abilities in order to determine need for physical therapy, occupational therapy, and assistive devices for ambulation, such as a wheelchair</p>
            </list-item>
          </list>
        </sec>
        <sec id="cco.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Although it is unknown how CCD is associated with malignant hyperthermia susceptibility or which pathogenic variants in <italic toggle="yes">RYR1</italic> are absolutely related to MH susceptibility, it is prudent for individuals with CCD to avoid inhalational anesthetics and succinylcholine. See <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object> for more details.</p>
          <p>Individuals suspected of having MH susceptibility are advised to avoid extremes of heat, but this does not mean restriction of athletic activity.</p>
        </sec>
        <sec id="cco.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Because CCD is associated with an increased risk for MH susceptibility, it is appropriate to test at-risk relatives of a proband (whether symptomatic or not) for the <italic toggle="yes">RYR1</italic> pathogenic variant identified in the proband in order to caution those with the pathogenic variant about potential risks of inhalational anesthetics and succinylcholine. See <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object> for more details.</p>
          <p>See <xref ref-type="sec" rid="cco.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cco.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Because all patients with CCD are considered to be at risk for <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">malignant hyperthermia</related-object>, inhalational anesthetics and succinylcholine should be avoided while considering general or regional anesthesia for delivery. Similar to most neuromuscular disorders, clinical progression of disease can be expected in CCD [<xref ref-type="bibr" rid="cco.REF.sax.2006.559">Sax &#x00026; Rosenbaum 2006</xref>].</p>
        </sec>
        <sec id="cco.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="cco.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cco.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Central core disease (CCD) is usually inherited in an autosomal dominant manner, but may be inherited in an autosomal recessive manner [<xref ref-type="bibr" rid="cco.REF.ferreiro.2002a.750">Ferreiro et al 2002a</xref>, <xref ref-type="bibr" rid="cco.REF.jungbluth.2002.284">Jungbluth et al 2002</xref>, <xref ref-type="bibr" rid="cco.REF.romero.2003.2341">Romero et al 2003</xref>, <xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al 2006</xref>, <xref ref-type="bibr" rid="cco.REF.zhou.2006b.2791">Zhou et al 2006b</xref>, <xref ref-type="bibr" rid="cco.REF.kossugue.2007.670">Kossugue et al 2007</xref>].</p>
        </sec>
        <sec id="cco.Risk_to_Family_Members__Autosomal_Do">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with autosomal dominant CCD have an affected parent or an asymptomatic parent who has an <italic toggle="yes">RYR1</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>A proband with autosomal dominant CCD may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The proportion of cases caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include muscle biopsy and molecular genetic testing.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with CCD may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations/ molecular genetic testing have been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>Note: If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected.</p>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs of inheriting the <italic toggle="yes">RYR1</italic> pathogenic variant is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low. However, the sibs of a proband with clinically unaffected parents are still at increased risk for CCD because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with autosomal dominant CCD has a 50% chance of inheriting the pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members may be at risk.</p>
        </sec>
        <sec id="cco.Risk_to_Family_Members__Autosomal_Re">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">RYR1</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are often asymptomatic. Although it is unknown which pathogenic variants in <italic toggle="yes">RYR1</italic> are related to MH susceptibility, it is prudent for individuals with <italic toggle="yes">RYR1</italic> variants to avoid inhalational anesthetics and succinylcholine. See <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object> for more details.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are generally asymptomatic. Although it is unknown which pathogenic variants in <italic toggle="yes">RYR1</italic> are related to MH susceptibility, it is prudent for individuals with <italic toggle="yes">RYR1</italic> variants to avoid inhalational anesthetics and succinylcholine. See <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">Malignant Hyperthermia Susceptibility</related-object> for more details.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with autosomal recessive CCD are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">RYR1</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="cco.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for family members at risk of being heterozygous for autosomal recessive CCD requires prior identification of the <italic toggle="yes">RYR1</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="cco.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="cco.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on testing of relatives for malignant hyperthermia susceptibility.</p>
          <p><bold>Testing of at-risk asymptomatic relatives</bold> of individuals with central core disease is possible after molecular genetic testing has identified the specific pathogenic variant(s) in the family. Such testing should be performed in the context of formal genetic counseling. This testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.</p>
          <p><bold>Simplex cases.</bold>
<xref ref-type="bibr" rid="cco.REF.kossugue.2007.670">Kossugue et al [2007]</xref> reported several simplex cases with CCD in whom at least one pathogenic variant was identified. The cause of CCD in these individuals may be (1) a <italic toggle="yes">de novo</italic> dominant pathogenic variant or (2) autosomal recessive inheritance of a known <italic toggle="yes">RYR1</italic> pathogenic variant and a second as-yet unidentified pathogenic variant.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with autosomal dominant CCD has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="cco.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">RYR1</italic> pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for CCD are possible.</p>
          <p>Requests for prenatal testing for conditions which (like most cases of central core disease) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="cco.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cco.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="cco.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The skeletal muscle isoform of ryanodine receptor 1 (RyR1) mediates Ca<sup>2+</sup> release during excitation-contraction (EC) coupling; hence, pathogenic variants in <italic toggle="yes">RYR1</italic> are expected to cause disturbance in this process. Two fundamentally distinct cellular mechanisms (leaky channels and EC uncoupling) are proposed to explain how altered release channel function caused by different pathogenic variants in <italic toggle="yes">RYR1</italic> could result in muscle weakness in CCD [<xref ref-type="bibr" rid="cco.REF.dirksen.2002.189">Dirksen &#x00026; Avila 2002</xref>]. Although it is commonly believed that cores are not specific to CCD, it has been demonstrated that calcium-handling proteins are abnormally distributed in <italic toggle="yes">RYR1</italic>-associated core myopathies: RyR1 protein was depleted from the cores, while calsequestrin, SERCA1/2, triadin, and DHPR had accumulated within or around the lesions [<xref ref-type="bibr" rid="cco.REF.herasse.2007.57">Herasse et al 2007</xref>]. These findings suggest that EC uncoupling may indeed lead to muscle weakness. The muscle weakness can be at least partially explained by a reduced magnitude of voltage-gated Ca2+ release. Recently, it has been shown that <italic toggle="yes">RYR1</italic> pathogenic variants can alter the expression of the gene <italic toggle="yes">SERCA</italic>, which could explain the paradoxic finding of calcium store depletion in the sarcoplasmic reticulum [<xref ref-type="bibr" rid="cco.REF.vega.2011.4649">Vega et al 2011</xref>]. Interestingly, the EC coupling changes has been shown to be reversed by administration of calcitonin gene-related peptide, at least in the cell culture model.</p>
          <p>Certain <italic toggle="yes">RYR1</italic> pathogenic variants are associated with both CCD and MH susceptibility. The effects of pathogenic variants that involve CCD plus MH susceptibility and MH susceptibility only on Ca<sup>2+</sup> handling and EC coupling have been characterized; it has been suggested that sarcoplasmic reticulum (SR) Ca<sup>2+</sup> depletion and increased basal Ca<sup>2+</sup> levels are preferentially associated with <italic toggle="yes">RYR1</italic> pathogenic variants that result in combined MH susceptibility and CCD [<xref ref-type="bibr" rid="cco.REF.dirksen.2004.3193">Dirksen &#x00026; Avila 2004</xref>]. Furthermore, the authors found that MH susceptibility-only pathogenic variants modestly increase basal release-channel activity in a manner insufficient to alter net SR Ca<sup>2+</sup> content ("compensated leak"), whereas the combined MH susceptibility and CCD phenotype arises from pathogenic variants that enhance basal activity to a level sufficient to promote SR Ca<sup>2+</sup> depletion, elevate [Ca<sup>2+</sup>]i, and reduce maximal VGCR ("decompensated leak").</p>
          <p><xref ref-type="bibr" rid="cco.REF.zhou.2006a.859">Zhou et al [2006a]</xref> presented evidence that in individuals with autosomal recessive core myopathies, <italic toggle="yes">RYR1</italic> frequently undergoes polymorphic, tissue-specific, and developmentally regulated allele silencing apparently mediated by hypermethylation. The resulting monoallelic expression of <italic toggle="yes">RYR1</italic> can unveil recessive pathogenic variants in the remaining <italic toggle="yes">RYR1</italic> allele in persons with core myopathies. <xref ref-type="bibr" rid="cco.REF.zhou.2006a.859">Zhou et al [2006a]</xref> also suggested that imprinting is a likely mechanism for this phenomenon, which can play a role in human phenotypic heterogeneity and in irregularities of inheritance patterns.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">RYR1</italic> consists of 106 exons (2 of which are alternatively spliced) encompassing a total of 160 kb and producing one of the largest proteins in humans with 5038 amino acids [<xref ref-type="bibr" rid="cco.REF.phillips.1996.24">Phillips et al 1996</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="cco" object-id="cco.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign variants.</bold> Several benign variants have been noted in <italic toggle="yes">RYR1</italic>, including: p.Ala1832Gly, p.Val2550Leu [<xref ref-type="bibr" rid="cco.REF.monnier.2000.2599">Monnier et al 2000</xref>]; p.Val4849Ile [<xref ref-type="bibr" rid="cco.REF.monnier.2001.2581">Monnier et al 2001</xref>]; p.Gly2060Cys, and p.Met485Val [<xref ref-type="bibr" rid="cco.REF.zhou.2006b.2791">Zhou et al 2006b</xref>]. See <xref ref-type="table" rid="cco.T.selected_ryr1_benign_variants">Table 2</xref>.</p>
          <table-wrap id="cco.T.selected_ryr1_benign_variants" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">RYR1</italic> Benign Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met485Val</td>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000540.2">NM_000540.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000531.2">NP_000531.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala1832Gly</td>
                </tr>
                <tr>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val2550Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val4849Ile</td>
                </tr>
                <tr>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_cco.T.selected_ryr1_benign_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly2060Cys</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Pathogenic variants.</bold> More than 200 reported <italic toggle="yes">RYR1</italic> pathogenic variants have been associated with the autosomal dominant or autosomal recessive forms of CCD, and most of them are pathogenic missense variants few deletions and cryptic site variants, clustered in three regions of the gene. More than half of the <italic toggle="yes">RYR1</italic> pathogenic variants are private.</p>
          <p>The <italic toggle="yes">RYR1</italic> pathogenic variants associated with CCD identified so far are clustered in three relatively restricted regions ("hot spots"), which encode domain 1 (exons 1-17), domain 2 (exons 39-46), and domain 3 (exons 90-104) of the ryanodine receptor 1 [<xref ref-type="bibr" rid="cco.REF.treves.2005.577">Treves et al 2005</xref>] (<xref ref-type="fig" rid="cco.F2">Figure 2</xref>).</p>
          <p>Although most pathogenic variants associated with CCD are clustered in the C-terminal domain 3, which comprises the transmembrane/luminal and pore-forming region of the channel, studies have shown that pathogenic variants in CCD are likewise found in domains 1 and 2, in which pathogenic variants are more commonly associated with malignant hyperthermia (see <xref ref-type="sec" rid="cco.Genetically_Related_Allelic_Disorder">Allelic Disorders</xref>).</p>
          <p>The most common pathogenic variants are shown in <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cco-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf).</p>
          <p><inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cco-Table4.pdf" content-type="local-data">Table 4</inline-supplementary-material> (pdf) shows the most common <italic toggle="yes">RYR1</italic> pathogenic amino acid variants associated with autosomal dominant central core disease.</p>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">RYR1</italic> encodes the ryanodine receptor 1 protein, a skeletal muscle calcium-release channel located in the sarcoplasmic reticulum (SR). The functional channel is a homotetramer of 560-kd subunits; it releases calcium stored in the SR in response to membrane depolarization transduced by the dihydropyridine receptor (DHPR). The cytoplasmic domain of ryanodine receptor 1, also called the foot structure, comprises the first 4000 amino acids that bridge the gap between the SR and the transverse tubular system. The last 1000 amino acids from the transmembrane domain contain the pore of the channel [<xref ref-type="bibr" rid="cco.REF.tilgen.2001.2879">Tilgen et al 2001</xref>, <xref ref-type="bibr" rid="cco.REF.lehmannhorn.2003">Lehmann-Horn et al 2003</xref>].</p>
          <p>Ryanodine receptors belong to the superfamily of intracellular Ca<sup>2+</sup> release channels present on endoplasmic reticulum/sarcoplasmic reticulum (SR) membranes, having three different isoforms. Functional units are homotetramers of approximately 5,000 amino acids per subunit coded by 150-kb genes. <italic toggle="yes">RYR1</italic>, forming the SR calcium release channel, has a large hydrophilic NH<sub>2</sub>-terminal domain and a hydrophobic COOH-terminal domain containing several transmembrane domains as well as the channel pore. The 563-kd protein is predominantly expressed not only in skeletal muscle but also in human B-lymphocytes and immature murine dendritic cells.</p>
          <p><bold>Abnormal gene product.</bold> Alterations in the ryanodine receptor 1 protein lead to an abnormal, sustained increase in myoplasmic calcium concentration in skeletal muscle because of a "leaky channel" or uncoupling with its voltage sensor, which is encoded by the voltage-gated calcium channel gene <italic toggle="yes">DHPR</italic> [<xref ref-type="bibr" rid="cco.REF.nelson.2001.169">Nelson 2001</xref>, <xref ref-type="bibr" rid="cco.REF.wehner.2003.203">Wehner et al 2003</xref>].</p>
          <p>In vitro studies suggest that a high basal activity of the mutated Ca<sup>2+</sup> channel could explain the muscle weakness and muscle atrophy observed in persons with CCD in one family [<xref ref-type="bibr" rid="cco.REF.lynch.1999.4164">Lynch et al 1999</xref>]. In vitro expression of ryanodine receptor 1 with a single pathogenic variant (p.Ile4898Thr) in the C-terminal transmembrane/luminal domain in HEK293 cells resulted in loss of channel activation and reduction in ryanodine binding, possibly by disrupting the ligand binding site located in the C terminus of the protein. Further analysis, however, showed that this pathogenic variant leads to a significant increase in the sensitivity of the channel to the activating effects of calcium.</p>
          <p>The association of C-terminal pathogenic variants with clinically evident muscle weakness may be explained by the leaky-channel model and the excitation-contraction (EC) uncoupling model.</p>
          <p>Some non-C-terminal pathogenic variants in ryanodine receptor 1 promote the leak of Ca<sup>2+</sup> ions from the SR that may or may not be compensated by the activity of the sarco-endoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA), resulting in elevation of resting cytosolic Ca<sup>2+</sup> and depletion of SR Ca<sup>2+</sup> stores.</p>
          <p>C-terminal pathogenic variants, especially those in the pore region of ryanodine receptor 1, may directly affect the channel gating properties, resulting in an abolition of orthograde activation by the voltage-gated L-type Ca<sup>2+</sup> channel or, in other words, EC uncoupling. However, no compensatory mechanism increases Ca<sup>2+</sup> release as the SERCA pumps do in the leaky model. Nevertheless, the effect of pathogenic variants in the C-terminal region remains controversial because a number of pathogenic variants in this area were also shown to be "leaky." Interestingly, several pathogenic variants in <italic toggle="yes">RYR1</italic> exon 102 were shown to lead to varying degrees of EC uncoupling, indicating that this region is a primary locus of EC uncoupling in CCD [<xref ref-type="bibr" rid="cco.REF.avila.2003.277">Avila et al 2003</xref>].</p>
        </sec>
      </sec>
      <sec id="cco.References">
        <title>References</title>
        <sec id="cco.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cco.Literature_Cited.reflist0">
            <ref id="cco.REF.agrawal.2007.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agrawal</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenleaf</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomczak</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehtokari</surname>
                    <given-names>VL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallgren-Pettersson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallefeld</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darras</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maciver</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dormitzer</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beggs</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2.</article-title>
                <source>Am J Hum Genet</source>
                <volume>80</volume>
                <fpage>162</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17160903</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.avila.2003.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Avila</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Connell</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirksen</surname>
                    <given-names>RT</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease.</article-title>
                <source>J Gen Physiol</source>
                <volume>121</volume>
                <fpage>277</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">12642598</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.boncompagni.2009.21996">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boncompagni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Micaroni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamilton</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirksen</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franzini-Armstrong</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Protasi</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Characterization and temporal development of cores in a mouse model of malignant hyperthermia.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>2009</year>
                <volume>106</volume>
                <fpage>21996</fpage>
                <lpage>2001</lpage>
                <pub-id pub-id-type="pmid">19966218</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.davis.2003.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>North</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuntzer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bankier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomlinson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagarajan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colley</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedeon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>NG</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Principal mutation hot spot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>13</volume>
                <fpage>151</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12565913</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.dirksen.2002.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dirksen</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avila</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2+) release channels?</article-title>
                <source>Trends Cardiovasc Med</source>
                <volume>12</volume>
                <fpage>189</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">12161072</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.dirksen.2004.3193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dirksen</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avila</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1.</article-title>
                <source>Biophys J</source>
                <volume>87</volume>
                <fpage>3193</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">15347586</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.ferreiro.2002a.750">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haenggeli</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>WD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivoche</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemainque</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002a</year>
                <article-title>A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene.</article-title>
                <source>Ann Neurol</source>
                <volume>51</volume>
                <fpage>750</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12112081</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.ferreiro.2002b.739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pichereau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moghadaszadeh</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goemans</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002b</year>
                <article-title>Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies.</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>739</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">12192640</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.fischer.2006.2217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herasse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barrag&#x000e1;n-Campos</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiras</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viollet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maugenre</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Muscle imaging in dominant core myopathies linked or unlinked to the ryanodine receptor 1 gene.</article-title>
                <source>Neurology</source>
                <volume>67</volume>
                <fpage>2217</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">17190947</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.herasse.2007.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herasse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parain</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marty</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaindl</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Abnormal distribution of calcium-handling proteins: a novel distinctive marker in core myopathies.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>66</volume>
                <fpage>57</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">17204937</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.ibarra.2006.1146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ibarra</surname>
                    <given-names>M CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murayama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minami</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichihara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochiai</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.</article-title>
                <source>Anesthesiology</source>
                <volume>104</volume>
                <fpage>1146</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">16732084</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.ilkovski.2001.1333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ilkovski</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nowak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schnell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durling</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roddick</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilkinson</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornberg</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunning</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardeman</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>North</surname>
                    <given-names>KN</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>68</volume>
                <fpage>1333</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">11333380</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.jungbluth.2004.785">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Counsell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allsop</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chattopadhyay</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messina</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bydder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>14</volume>
                <fpage>785</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">15564033</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.jungbluth.2002.284">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halliger-Keller</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brockington</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feng</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chattopadhyay</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzur</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roper</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bydder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores.</article-title>
                <source>Neurology</source>
                <volume>59</volume>
                <fpage>284</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12136074</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.jungbluth.2007.338">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robb</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treves</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitoun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buj-Bello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;nnenman</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Centronuclear myopathy due to a dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.</article-title>
                <source>Neuromusc Disord</source>
                <volume>17</volume>
                <fpage>338</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">17376685</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.kaindl.2004.842">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaindl</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruschendorf</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krause</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goebel</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koehler</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongratz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller-Hocker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nurnberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoltenburg-Didinger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lochmuller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huebner</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Missense mutations of ACTA1 cause dominant congenital myopathy with cores.</article-title>
                <source>J Med Genet</source>
                <volume>41</volume>
                <fpage>842</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15520409</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.kossugue.2007.670">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kossugue</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paim</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavanello</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurgel-Giannetti</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zatz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vainzof</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Central core disease due to recessive mutations in RYR1 gene: Is it more common than described?</article-title>
                <source>Muscle Nerve</source>
                <volume>35</volume>
                <fpage>670</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17226826</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.lehmannhorn.2003">
              <mixed-citation publication-type="book">Lehmann-Horn F, Lerche H, Jurkatt-Rott K. Skeletal muscle channelopathies: myotonias, periodic paralyses and malignant hyperthermia. In: Stalber E, ed. <italic toggle="yes">Clinical Neurophysiology of Disorders of Muscle and Neuromuscular Junction, Including Fatigue (Handbook of Clinical Neurophysiology</italic>), vol 2. Amsterdam, Netherlands: Elsevier; 2003:457-83.</mixed-citation>
            </ref>
            <ref id="cco.REF.lillis.2012">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lillis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: Central core disease.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <issue>2</issue>
                <pub-id pub-id-type="pmid">21989361</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.lynch.1999.4164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehane</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mallet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giblin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heffron</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaughan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zafra</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLennan</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCarthy</surname>
                    <given-names>TV</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>96</volume>
                <fpage>4164</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10097181</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.monnier.2001.2581">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerale</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landrieu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivoche</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor.</article-title>
                <source>Hum Mol Genet</source>
                <volume>10</volume>
                <fpage>2581</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">11709545</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.monnier.2000.2599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerale</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivoche</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLennan</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.</article-title>
                <source>Hum Mol Genet</source>
                <volume>9</volume>
                <fpage>2599</fpage>
                <lpage>608</lpage>
                <pub-id pub-id-type="pmid">11063719</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.nelson.2001.169">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>TE</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Heat production during anesthetic-induced malignant hyperthermia.</article-title>
                <source>Biosci Rep</source>
                <volume>21</volume>
                <fpage>169</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">11725865</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.norwood.2009.3175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Norwood</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harling</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eagle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.</article-title>
                <source>Brain.</source>
                <year>2009</year>
                <volume>132</volume>
                <fpage>3175</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">19767415</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.phillips.1996.24">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujii</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khanna</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeLeon</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokobata</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jong</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLennan</surname>
                    <given-names>DH</given-names>
                  </name>
                </person-group>
                <article-title>The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene.</article-title>
                <source>Genomics.</source>
                <year>1996</year>
                <volume>34</volume>
                <fpage>24</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">8661021</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.quinlivan.2003.1051">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dwyer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dove</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Central core disease: clinical, pathological, and genetic features.</article-title>
                <source>Arch Dis Child</source>
                <volume>88</volume>
                <fpage>1051</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14670767</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.romero.2003.2341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viollet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cortey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chevallay</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Dominant and recessive central core disease associated with RYR1 mutations and fetal akinesia.</article-title>
                <source>Brain</source>
                <volume>126</volume>
                <fpage>2341</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12937085</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.sato.2008.114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibarra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tojo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oh</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation.</article-title>
                <source>Neurology</source>
                <volume>70</volume>
                <fpage>114</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">17538032</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.sax.2006.559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sax</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <article-title>Neuromuscular disorders in pregnancy.</article-title>
                <source>Muscle Nerve.</source>
                <year>2006</year>
                <volume>34</volume>
                <fpage>559</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">16969835</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.sewry.2002.930">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dwyer</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dove</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furst</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helliwell</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laing</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinlivan</surname>
                    <given-names>RC</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The spectrum of pathology in central core disease.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>12</volume>
                <fpage>930</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12467748</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.shepherd.2004.e33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shepherd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellis</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halsall</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkins</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene.</article-title>
                <source>J Med Genet</source>
                <volume>41</volume>
                <fpage>e33</fpage>
                <pub-id pub-id-type="pmid">14985404</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.tilgen.2001.2879">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tilgen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halliger-Keller</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmucci</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hauser</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehmann-Horn</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treves</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis.</article-title>
                <source>Hum Mol Genet</source>
                <volume>10</volume>
                <fpage>2879</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">11741831</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.treves.2005.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Treves</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ducreux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Divet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleunven</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grasso</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paesante</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzato</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>15</volume>
                <fpage>577</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">16084090</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.vega.2011.4649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vega</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos-Mondrag&#x000f3;n</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calder&#x000f3;n-Rivera</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarain-Herzberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avila</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Calcitonin gene-related peptide restores disrupted excitation-contraction coupling in myotubes expressing central core disease mutations in RyR1.</article-title>
                <source>J Physiol.</source>
                <year>2011</year>
                <volume>589</volume>
                <fpage>4649</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">21825032</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.wehner.2003.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wehner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rueffert</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olthoff</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.</article-title>
                <source>Genet Test</source>
                <volume>7</volume>
                <fpage>203</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">14641996</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.wu.2006.1470">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibarra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malicdan</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murayama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichihara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Central core disease is due to RYR1 mutations in more than 90% of patients.</article-title>
                <source>Brain</source>
                <volume>129</volume>
                <fpage>1470</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">16621918</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.zhou.2006a.859">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brockington</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2006a</year>
                <article-title>Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies.</article-title>
                <source>Am J Hum Genet</source>
                <volume>79</volume>
                <fpage>859</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">17033962</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.zhou.2006b.2791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meissner</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treves</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006b</year>
                <article-title>Characterization of recessive RYR1 mutations in core myopathies.</article-title>
                <source>Hum Mol Genet</source>
                <volume>15</volume>
                <fpage>2791</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">16940308</pub-id>
              </element-citation>
            </ref>
            <ref id="cco.REF.zorzato.2003.379">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zorzato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meissner</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouliquin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treves</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical and functional effects of a deletion in a COOH-terminal lumenal loop of the skeletal muscle ryanodine receptor.</article-title>
                <source>Hum Mol Genet</source>
                <volume>12</volume>
                <fpage>379</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">12566385</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cco.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cco.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>4 December 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>11 May 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>16 May 2007 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>8 December 2006 (in) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="cco.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Histologic features of muscle observed in central core diseaseA-B. Sections from a nine-year-old depicting the classic description of CCDA. Pronounced type 2 fiber deficiency is seen with myosin ATPase staining with acidic pre-incubation (* shows type 2 fiber). B. In NADH-TR staining, central cores are seen in almost all fibers, with "rimming" of cores in some fibers (arrow).C-D. Sections from a 63-year-old showing the other features of cores seen in CCDC. Type 2 fiber deficiency is also seen but is not as marked as in A (* shows type 2 fiber). D. Cores are seen, but not in all type 1 fibers. Cores are sometimes found in the subsarcolemmal area or periphery of the fiber, and more than one core can be present in a single fiber (arrow). Cores lacking clearly demarcated borders, (arrowhead) can be seen in higher frequency.E-F. Sections from a three-year-old boy with cores and few fibers with rodsE. Nemaline bodies are observed with modified Gomori-trichrome staining (arrows). F. Few cores are seen in NADH-TR staining.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cco-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="cco.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p><italic toggle="yes">RYR1</italic> pathogenic variant map for CCDThe three shaded mutational hot spot areas: Exons 1-17 (domain 1) Exons 39-46 (domain 2) Exons 90-104 (domain 3)Closed circles = pathogenic missense variants Open circles = autosomal recessive pathogenic variants Triangles = deletionsThe most common pathogenic variants are shown in <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cco-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material> (pdf).Adapted from <xref ref-type="bibr" rid="cco.REF.wu.2006.1470">Wu et al [2006]</xref></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cco-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
